She currently serves as the Director of Intellectual Property at Qilu Pharmaceutical, with extensive experience in FTO (Freedom-to-Operate) analysis, intellectual property due diligence, domestic patent invalida tion and litigation, as well as IP matters related to ANDA (Abbreviated New Drug Application). She has ledpatent challenges for over 20 ANDA products in the United States, handled dozens of domestic patent

invalidation cases and other legal proceedings, and conducted intellectual property due diligence for nearly 100 projects.